Enzo Biochem Stock Price, News & Analysis (NYSE:ENZ)

$7.79 0.04 (0.52 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$7.75
Today's Range$7.69 - $7.85
52-Week Range$6.27 - $12.04
Volume163,934 shs
Average Volume196,150 shs
Market Capitalization$365.55 million
P/E Ratio-194.75
Dividend YieldN/A
Beta0.87

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem logoEnzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical & Diagnostic Laboratories
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:ENZ
CUSIPN/A
Phone+1-516-7555500

Debt

Debt-to-Equity RatioN/A
Current Ratio4.66%
Quick Ratio4.29%

Price-To-Earnings

Trailing P/E Ratio-194.75
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$107.80 million
Price / Sales3.39
Cash Flow$0.02 per share
Price / Cash330.75
Book Value$1.91 per share
Price / Book4.08

Profitability

Trailing EPS($0.04)
Net Income$-2,500,000.00
Net Margins-1.53%
Return on Equity-1.89%
Return on Assets-1.55%

Miscellaneous

Employees472
Outstanding Shares46,930,000

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) announced its quarterly earnings results on Thursday, December, 7th. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The medical research company had revenue of $27.68 million for the quarter, compared to analyst estimates of $27.51 million. Enzo Biochem had a negative net margin of 1.53% and a negative return on equity of 1.89%. View Enzo Biochem's Earnings History.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:

  • Barry W. Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director (Age 67)
  • Elazar Rabbani Ph.D., Chairman of the Board, Chief Executive Officer, Secretary (Age 74)
  • James M. O'Brien, Executive Vice President - Finance (Age 51)
  • Bruce A. Dey, Vice President - Sales and Marketing, Enzo Clinical Labs (Age 59)
  • Dieter Schapfel M.D., Chief Medical Director, Enzo Clinical Labs (Age 54)
  • Gregory M. Bortz, Lead Independent Director (Age 47)
  • Bruce A. Hanna Ph.D., Independent Director (Age 74)
  • Dov Perlysky, Independent Director (Age 55)

Who owns Enzo Biochem stock?

Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.95%) and Schwab Charles Investment Management Inc. (0.38%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?

Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Enzo Biochem company stock in the last year include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Insider Buying and Selling for Enzo Biochem.

How do I buy Enzo Biochem stock?

Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of Enzo Biochem stock can currently be purchased for approximately $7.79.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $365.55 million and generates $107.80 million in revenue each year. The medical research company earns $-2,500,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Enzo Biochem employs 472 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 60 EXECUTIVE BLVD, FARMINGDALE, NY 11735, United States. The medical research company can be reached via phone at +1-516-7555500.


MarketBeat Community Rating for Enzo Biochem (ENZ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzo Biochem (NYSE:ENZ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Enzo Biochem (NYSE:ENZ) Consensus Price Target History

Price Target History for Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Enzo Biochem (NYSE:ENZ) Earnings History and Estimates Chart

Earnings by Quarter for Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE ENZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/7/2017Q1 2018($0.01)($0.01)$27.51 million$27.68 millionViewListenView Earnings Details
3/13/2017Q2 2017($0.04)($0.02)$26.10 million$26.26 millionViewN/AView Earnings Details
12/8/2016Q117($0.05)($0.03)$25.90 million$26.28 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.00 million$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.00 million$25.18 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 million$23.99 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$24.20 million$23.09 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 million$24.82 millionViewListenView Earnings Details
10/9/2014Q4 2014($0.07)($0.06)$23.60 million$24.91 millionViewListenView Earnings Details
6/9/2014Q314($0.09)($0.05)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)ViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
3/12/2013Q2 2013($0.06)($0.14)ViewN/AView Earnings Details
12/10/2012Q1 2013($0.06)($0.09)ViewN/AView Earnings Details
10/15/2012Q4 2012($0.07)($0.11)ViewN/AView Earnings Details
6/11/2012Q3 2012($0.07)($0.09)ViewN/AView Earnings Details
3/12/2012Q2 2012($0.09)($0.11)ViewN/AView Earnings Details
12/12/2011Q1 2012($0.07)($0.12)ViewN/AView Earnings Details
10/14/2011Q4 2011($0.09)($0.11)ViewN/AView Earnings Details
6/9/2011Q3 2011($0.10)($0.05)ViewN/AView Earnings Details
3/14/2011Q2 2011($0.10)($0.15)ViewN/AView Earnings Details
12/13/2010Q1 2011($0.08)($0.03)ViewN/AView Earnings Details
10/14/2010Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
6/9/2010Q3 2010($0.08)($0.12)ViewN/AView Earnings Details
3/12/2010Q2 2010($0.08)($0.27)ViewN/AView Earnings Details
12/10/2009Q1 2010($0.10)($0.05)ViewN/AView Earnings Details
10/14/2009Q4 2009($0.05)($0.14)ViewN/AView Earnings Details
6/15/2009Q3 2009($0.08)ViewN/AView Earnings Details
3/12/2009Q2 2009($0.21)ViewN/AView Earnings Details
12/10/2008Q1 2009($0.04)($0.17)ViewN/AView Earnings Details
10/14/2008Q4 2008($0.06)($0.09)ViewN/AView Earnings Details
6/9/2008Q3 2008($0.07)($0.06)ViewN/AView Earnings Details
3/11/2008Q2 2008($0.12)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Enzo Biochem (NYSE:ENZ) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.02 EPS

Dividends

Dividend History for Enzo Biochem (NYSE:ENZ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Enzo Biochem (NYSE ENZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.90%
Institutional Ownership Percentage: 63.65%
Insider Trades by Quarter for Enzo Biochem (NYSE:ENZ)
Insider Trades by Quarter for Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE ENZ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/31/2017Gregory M BortzDirectorSell42,005$9.82$412,489.10292,875View SEC Filing  
10/27/2017James Michael O'brienEVPSell22,866$10.28$235,062.4834,886View SEC Filing  
10/25/2017Barry W WeinerCFOSell54,126$10.11$547,213.861,423,367View SEC Filing  
10/25/2017Elazar RabbaniCEOSell72,401$10.09$730,526.092,038,474View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enzo Biochem (NYSE ENZ) News Headlines

Source:
DateHeadline
Free Post Earnings Research Report: Enzo Biochem’s Revenue Grew 5%; Net Loss NarrowedFree Post Earnings Research Report: Enzo Biochem’s Revenue Grew 5%; Net Loss Narrowed
finance.yahoo.com - January 9 at 9:23 AM
Noteworthy Friday Option Activity: CSX, GLPI, ENZNoteworthy Friday Option Activity: CSX, GLPI, ENZ
www.nasdaq.com - December 15 at 6:04 PM
Blog Exposure - Cancer Genetics Announces Best Diagnostic Modality to Evaluate PD-L1 in Diffuse Large B-Cell LymphomasBlog Exposure - Cancer Genetics Announces Best Diagnostic Modality to Evaluate PD-L1 in Diffuse Large B-Cell Lymphomas
finance.yahoo.com - December 13 at 9:35 AM
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q1, 2018 By the Numbers : December 11, 2017Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q1, 2018 By the Numbers : December 11, 2017
finance.yahoo.com - December 11 at 5:41 PM
Enzo Biochem (ENZ) Q1 2018 Earnings Conference Call TranscriptEnzo Biochem (ENZ) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - December 11 at 5:41 PM
Edited Transcript of ENZ earnings conference call or presentation 8-Dec-17 1:30pm GMTEdited Transcript of ENZ earnings conference call or presentation 8-Dec-17 1:30pm GMT
finance.yahoo.com - December 9 at 9:24 AM
Enzo Biochem (ENZ) Releases Quarterly  Earnings Results, Hits EstimatesEnzo Biochem (ENZ) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - December 8 at 9:24 AM
Enzo Biochem, Inc. to Host Earnings CallEnzo Biochem, Inc. to Host Earnings Call
finance.yahoo.com - December 8 at 9:18 AM
ETFs with exposure to Enzo Biochem, Inc. : December 7, 2017ETFs with exposure to Enzo Biochem, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem reports 1Q lossEnzo Biochem reports 1Q loss
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem Reports Improved First Quarter ResultsEnzo Biochem Reports Improved First Quarter Results
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.
finance.yahoo.com - December 5 at 10:01 AM
Global Healthcare Biomarkers Market Size will Exceed US$ 56 Billion By 2022Global Healthcare Biomarkers Market Size will Exceed US$ 56 Billion By 2022
www.marketwatch.com - November 16 at 1:55 PM
Enzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 SharesEnzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
James Michael Obrien Sells 22,866 Shares of Enzo Biochem, Inc. (ENZ) StockJames Michael O'brien Sells 22,866 Shares of Enzo Biochem, Inc. (ENZ) Stock
www.americanbankingnews.com - October 30 at 11:28 PM
Insider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 54,126 Shares of StockInsider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 54,126 Shares of Stock
www.americanbankingnews.com - October 27 at 8:40 PM
Insider Selling: Enzo Biochem, Inc. (ENZ) CEO Sells 72,401 Shares of StockInsider Selling: Enzo Biochem, Inc. (ENZ) CEO Sells 72,401 Shares of Stock
www.americanbankingnews.com - October 27 at 8:40 PM
ETFs with exposure to Enzo Biochem, Inc. : October 24, 2017ETFs with exposure to Enzo Biochem, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 10:08 PM
Enzo Biochem Announces NYS Department of Healths Approval of a New Womens Health Infectious Disease Panel - Business Wire (press release)Enzo Biochem Announces NYS Department of Health's Approval of a New Women's Health Infectious Disease Panel - Business Wire (press release)
www.businesswire.com - October 23 at 9:02 PM
Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s Health Infectious Disease PanelEnzo Biochem Announces NYS Department of Health’s Approval of a New Women’s Health Infectious Disease Panel
finance.yahoo.com - October 23 at 3:59 PM
What Investors Should Know About Enzo Biochem Inc’s (ENZ) Financial StrengthWhat Investors Should Know About Enzo Biochem Inc’s (ENZ) Financial Strength
finance.yahoo.com - October 21 at 10:36 PM
Enzo Biochem Enters Oversold Territory (ENZ)Enzo Biochem Enters Oversold Territory (ENZ)
www.thestreet.com - October 17 at 8:32 PM
ETFs with exposure to Enzo Biochem, Inc. : October 13, 2017ETFs with exposure to Enzo Biochem, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:52 PM
Earnings Review and Free Research Report: Enzo Biochem’s Q4 and Annual Top-line Rise on a Y-o-Y BasisEarnings Review and Free Research Report: Enzo Biochem’s Q4 and Annual Top-line Rise on a Y-o-Y Basis
finance.yahoo.com - October 10 at 4:04 PM
Enzo Biochem, Inc. (ENZ) Downgraded by TheStreetEnzo Biochem, Inc. (ENZ) Downgraded by TheStreet
www.americanbankingnews.com - October 2 at 5:08 PM
Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 28, 2017Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 28, 2017
finance.yahoo.com - October 2 at 2:58 PM
Enzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017Enzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017
finance.yahoo.com - October 2 at 2:58 PM
Edited Transcript of ENZ earnings conference call or presentation 28-Sep-17 12:30pm GMTEdited Transcript of ENZ earnings conference call or presentation 28-Sep-17 12:30pm GMT
finance.yahoo.com - October 2 at 2:58 PM
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 2:58 PM
ETFs with exposure to Enzo Biochem, Inc. : October 2, 2017ETFs with exposure to Enzo Biochem, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 2:58 PM
Earnings Scheduled For September 27, 2017 - BenzingaEarnings Scheduled For September 27, 2017 - Benzinga
www.benzinga.com - September 29 at 2:52 PM
Enzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017 - NasdaqEnzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017 - Nasdaq
www.nasdaq.com - September 29 at 2:52 PM
Enzo Biochems (ENZ) Q4 2017 Results - Earnings Call TranscriptEnzo Biochem's (ENZ) Q4 2017 Results - Earnings Call Transcript
www.msn.com - September 28 at 5:51 PM
Investor Network: Enzo Biochem, Inc. to Host Earnings CallInvestor Network: Enzo Biochem, Inc. to Host Earnings Call
www.baystreet.ca - September 28 at 9:44 AM
Enzo Biochem Reports Increase in Revenues and Profitable Fourth QuarterEnzo Biochem Reports Increase in Revenues and Profitable Fourth Quarter
www.businesswire.com - September 27 at 6:33 PM
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8 ... - Business Wire (press release)Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8 ... - Business Wire (press release)
www.businesswire.com - September 23 at 3:27 AM
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.
finance.yahoo.com - September 22 at 5:23 PM
Enzo Biochem Is Now Oversold (ENZ)Enzo Biochem Is Now Oversold (ENZ)
www.thestreet.com - September 19 at 6:20 PM
Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 1, 2017Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 1, 2017
finance.yahoo.com - September 1 at 6:40 PM
Enzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017Enzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017
finance.yahoo.com - August 25 at 7:59 PM
Enzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : August 17, 2017Enzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : August 17, 2017
finance.yahoo.com - August 17 at 7:31 PM
BRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott LaboratoriesBRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories
www.reuters.com - August 16 at 9:03 PM
Geron's (GERN) Imetelstat Progressing Well, Setbacks ConcernGeron's (GERN) Imetelstat Progressing Well, Setbacks Concern
finance.yahoo.com - August 14 at 6:42 PM
The Medicines Company (MDCO) Q2 Loss Widens, Revenues MissThe Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
www.nasdaq.com - August 11 at 12:38 AM
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View RaisedPerrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
finance.yahoo.com - August 10 at 7:35 PM
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
finance.yahoo.com - August 10 at 7:35 PM
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales ImpressOrexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
finance.yahoo.com - August 9 at 6:28 PM
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View IntactJazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
finance.yahoo.com - August 9 at 6:28 PM
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
finance.yahoo.com - August 7 at 6:34 PM
Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues SurpassJuno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
finance.yahoo.com - August 4 at 6:33 PM

SEC Filings

Enzo Biochem (NYSE:ENZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enzo Biochem (NYSE:ENZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzo Biochem (NYSE ENZ) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.